ARTES Biotechnology and Burnet Institute recently published data on the efficient production of malaria vaccine candidates using virus-like particles (VLP) presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies.
https://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-favicon.png134134Melanie Piontekhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngMelanie Piontek2019-09-11 12:40:492019-09-12 14:34:17ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates
Meet us at the Bio-Europe Spring 2018 taking place in Vienna, Austria March 25 -27. Volker Jenzelewski, Director Technology at ARTES, will be present in the One-on-One Partnering presenting ARTES’ innovative range of cell line and process development solutions for bio-pharmaceutical and vaccine products.
https://artes-biotechnology.biz/wp-content/uploads/2016/11/Artes-Biotechnology-News-1.png200200Melanie Piontekhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngMelanie Piontek2018-12-03 15:09:272019-07-13 13:12:27SplitCore – the latest milestone in ARTES´ vaccine development offer
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates
ARTES Biotechnology and Burnet Institute recently published data on the efficient production of malaria vaccine candidates using virus-like particles (VLP) presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies.
ARTES attends BioEurope Spring 2019
Meet us at the Bio-Europe Spring 2018 taking place in Vienna, Austria March 25 -27. Volker Jenzelewski, Director Technology at ARTES, will be present in the One-on-One Partnering presenting ARTES’ innovative range of cell line and process development solutions for bio-pharmaceutical and vaccine products.
SplitCore – the latest milestone in ARTES´ vaccine development offer
ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the University of Freiburg, Germany.